



## **Needham & Company Biotechnology Conference to Webcast Alkermes' Corporate Presentation**

June 14, 2004

CAMBRIDGE, Mass., Jun 14, 2004 (BUSINESS WIRE) -- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by Needham & Company on Wednesday, June 16, 2004 at 10:30am EDT. The presentation will be webcast from The New York Palace Hotel in New York and may be accessed under the investor relation's tab at [www.alkermes.com](http://www.alkermes.com). The presentation will be archived for 14 days.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The company's lead commercial product, Risperdal(R) Consta(TM) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen, a division of Johnson & Johnson. The company's lead proprietary product candidate, Vivitrex(R) ((naltrexone) long-acting injection), is a once-a-month injection for the treatment of alcohol dependence. Alkermes has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technology and expertise. The company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

SOURCE: Alkermes, Inc.

Rebecca Peterson  
Director, Corporate Communications  
Alkermes, Inc.  
(617) 583-6378

Customize your Business Wire news & multimedia to match your needs.  
Get breaking news from companies and organizations worldwide.  
Logon for FREE today at [www.BusinessWire.com](http://www.BusinessWire.com).